Starpharma Holdings Limited (SPL) Price & Analysis

Compare

19 Followers

SPL Stock Chart & Stats

AU$0.38

AU$0.00(0.00%)

At close: Jan 09 4:00 PM EST

AU$0.38

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.08 - AU$0.53

Previous CloseN/A

Volume337.59K

Average Volume (3M)724.95K

Market Cap

AU$193.16M

Enterprise ValueAU$182.00M

Total Cash (Recent Filing)AU$18.25M

Total Debt (Recent Filing)AU$790.00K

Price to Earnings (P/E)27.6

Beta1.55

Next Earnings

Aug 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)<0.01

Shares Outstanding419,915,680

10 Day Avg. Volume366,126

30 Day Avg. Volume724,950

Financial Highlights & Ratios

PEG Ratio-0.19

Price to Book (P/B)1.93

Price to Sales (P/S)7.47

P/FCF Ratio-5.40

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)>-0.01

Revenue Forecast (FY)AU$15.80M

Bulls Say, Bears Say

Bulls Say

Proprietary Dendrimer Platform & Licensing ModelStarpharma’s proprietary dendrimer platform and multi-channel revenue model (licensing, milestones, royalties, materials) create durable, partner-driven income potential. Platform licensing lets partners fund development, spreading R&D risk and providing recurring partner-related revenues that support operations over months.

Sustained Revenue GrowthPositive revenue growth indicates strengthening commercial traction and partner activity, expanding the company’s top-line base. Over the medium term this trend supports milestone and materials revenue potential and can help absorb R&D costs as partnerships mature and bolster recurring cash inflows.

Conservative Leverage And Solid Capital StructureLow leverage and a healthy equity ratio provide financial flexibility and lower refinancing risk while the company invests in development. This conservative balance sheet supports continued R&D and partnership investment without immediate debt pressure, preserving runway and optionality across medium-term programs.

Bears Say

Negative Operating And Free Cash FlowPersistent negative operating and free cash flow signal cash burn and limited internal funding for programs. This creates reliance on external capital or partner payments to fund operations and milestones, increasing dilution or financing risk over the next several months if cash generation does not improve.

Ongoing Unprofitability And Weak MarginsNegative EBIT and net margins indicate the business is not yet converting revenue into sustainable profits. Continued margin deficits reduce retained earnings and the company’s ability to self-fund growth, making it dependent on partnerships or financing until structural profitability is achieved.

Negative Return On EquityA negative ROE suggests capital is not generating acceptable returns and raises concerns about capital allocation and long-term shareholder value creation. If ROE remains negative, investor support and ability to raise non-dilutive capital could weaken, pressuring strategic options over months.

Starpharma Holdings Limited News

UBS Group Ceases to Be Substantial Shareholder in Starpharma

Starpharma Holdings Limited ( ($AU:SPL) ) just unveiled an update. UBS Group AG and its related bodies corporate...

9d ago

Starpharma Ramps Up DEP® Partnerships and Radiopharma Pipeline as Viraleze™ Sales Surge

Starpharma Holdings Limited ( ($AU:SPL) ) has issued an announcement. Starpharma reported a highly active second quarter of...

2M ago

Starpharma Seeks ASX Quotation for 1.69 Million New Ordinary Shares

The latest update is out from Starpharma Holdings Limited ( ($AU:SPL) ). Starpharma Holdings Limited has applied to...

2M ago

Starpharma Announces Lapse of 381,810 Performance Rights

Starpharma Holdings Limited ( ($AU:SPL) ) just unveiled an update. Starpharma Holdings Limited has notified the market that...

2M ago

Starpharma CEO Receives New Performance Rights

Starpharma Holdings Limited ( ($AU:SPL) ) has provided an announcement. Starpharma Holdings Limited announced a change in the...

3M ago

Starpharma Issues Unquoted Securities to Boost Employee Incentives

The latest update is out from Starpharma Holdings Limited ( ($AU:SPL) ). Starpharma Holdings Limited has announced the...

3M ago

Starpharma Announces Successful 2025 AGM Results

Starpharma Holdings Limited ( ($AU:SPL) ) just unveiled an update. Starpharma Holdings Limited announced the results of its...

4M ago

Starpharma Announces Strategic Partnerships and Growth at AGM

The latest announcement is out from Starpharma Holdings Limited ( ($AU:SPL) ). Starpharma Holdings Limited announced significant progress...

4M ago

Starpharma Secures Key Partnerships and Advances Strategic Initiatives in Q1 FY26

The latest update is out from Starpharma Holdings Limited ( ($AU:SPL) ). Starpharma Holdings Limited has announced significant...

5M ago

Starpharma Receives $5.5 Million Upfront Payment from Genentech for Oncology Collaboration

Starpharma Holdings Limited ( ($AU:SPL) ) has provided an announcement. Starpharma Holdings Limited has received an upfront payment...

5M ago

SPL FAQ

What was Starpharma Holdings Limited’s price range in the past 12 months?

Starpharma Holdings Limited lowest share price was AU$0.08 and its highest was AU$0.53 in the past 12 months.

What is Starpharma Holdings Limited’s market cap?

Starpharma Holdings Limited’s market cap is AU$193.16M.

When is Starpharma Holdings Limited’s upcoming earnings report date?

Starpharma Holdings Limited’s upcoming earnings report date is Aug 26, 2026 which is in 159 days.

How were Starpharma Holdings Limited’s earnings last quarter?

Starpharma Holdings Limited released its earnings results on Feb 17, 2026. The company reported AU$0.003 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.003.

Is Starpharma Holdings Limited overvalued?

According to Wall Street analysts Starpharma Holdings Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Starpharma Holdings Limited pay dividends?

Starpharma Holdings Limited does not currently pay dividends.

What is Starpharma Holdings Limited’s EPS estimate?

Starpharma Holdings Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Starpharma Holdings Limited have?

Starpharma Holdings Limited has 419,915,680 shares outstanding.

What happened to Starpharma Holdings Limited’s price movement after its last earnings report?

Starpharma Holdings Limited reported an EPS of AU$0.003 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.042%.

Which hedge fund is a major shareholder of Starpharma Holdings Limited?

Currently, no hedge funds are holding shares in AU:SPL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Starpharma Holdings Limited Stock Smart Score

Neutral

Fundamentals

Return on Equity

-15.96%

Trailing 12-Months

Asset Growth

-4.84%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Starpharma Holdings Limited

Starpharma Holdings Limited (SPL) is an Australian biotechnology company focused on the development of innovative drug delivery systems and new therapeutic products. The company specializes in dendrimer technology, which allows for enhanced delivery of drugs and provides unique solutions in various sectors, including pharmaceuticals and personal care. SPL's core products include its proprietary VivaGel, a dendrimer-based gel for the treatment of bacterial vaginosis and prevention of sexually transmitted infections, as well as collaborations in the development of oncology drugs.